New drug combo takes on Hard-to-Treat cancers

NCT ID NCT06480552

Recruiting now Disease control Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an experimental drug called TEV-56278, alone or with the immunotherapy pembrolizumab, in 240 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants will be treated for up to 12 months, with possible extension.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TEV-56278 (an experimental drug) and pembrolizumab (a cancer immunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early Phase 1 trial with only 240 participants, so the drug may not prove effective or safe enough to advance. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Teva Investigational Site 11282
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Teva Investigational Site 12014
RECRUITING

Huntersville, North Carolina, 28078, United States
Teva Investigational Site 12015
RECRUITING

Detroit, Michigan, 48201, United States
Teva Investigational Site 12016
RECRUITING

Chicago, Illinois, 60611, United States
Teva Investigational Site 12017
RECRUITING

Los Angeles, California, 90025, United States
Teva Investigational Site 12018
RECRUITING

Fairfax, Virginia, 22031, United States
Teva Investigational Site 12019
RECRUITING

Nashville, Tennessee, 37203, United States
Teva Investigational Site 12021
COMPLETED

Lake Mary, Florida, 32746, United States
Teva Investigational Site 12023
RECRUITING

Cincinnati, Ohio, 45219, United States
Teva Investigational Site 12024
RECRUITING

Nashville, Tennessee, 37232, United States
Teva Investigational Site 12025
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Teva Investigational Site 12058
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.